BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

796 related articles for article (PubMed ID: 12717389)

  • 1. Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells.
    Koga H; Harada M; Ohtsubo M; Shishido S; Kumemura H; Hanada S; Taniguchi E; Yamashita K; Kumashiro R; Ueno T; Sata M
    Hepatology; 2003 May; 37(5):1086-96. PubMed ID: 12717389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines.
    Koga H; Sakisaka S; Harada M; Takagi T; Hanada S; Taniguchi E; Kawaguchi T; Sasatomi K; Kimura R; Hashimoto O; Ueno T; Yano H; Kojiro M; Sata M
    Hepatology; 2001 May; 33(5):1087-97. PubMed ID: 11343236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells.
    Motomura W; Takahashi N; Nagamine M; Sawamukai M; Tanno S; Kohgo Y; Okumura T
    Int J Cancer; 2004 Jan; 108(1):41-6. PubMed ID: 14618613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines.
    Bae MA; Rhee H; Song BJ
    Toxicol Lett; 2003 Mar; 139(1):67-75. PubMed ID: 12595159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells.
    Motomura W; Okumura T; Takahashi N; Obara T; Kohgo Y
    Cancer Res; 2000 Oct; 60(19):5558-64. PubMed ID: 11034103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
    Di Gennaro E; Barbarino M; Bruzzese F; De Lorenzo S; Caraglia M; Abbruzzese A; Avallone A; Comella P; Caponigro F; Pepe S; Budillon A
    J Cell Physiol; 2003 Apr; 195(1):139-50. PubMed ID: 12599217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Troglitazone induces G1 arrest by p27(Kip1) induction that is mediated by inhibition of proteasome in human gastric cancer cells.
    Takeuchi S; Okumura T; Motomura W; Nagamine M; Takahashi N; Kohgo Y
    Jpn J Cancer Res; 2002 Jul; 93(7):774-82. PubMed ID: 12149143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators.
    Yin F; Wakino S; Liu Z; Kim S; Hsueh WA; Collins AR; Van Herle AJ; Law RE
    Biochem Biophys Res Commun; 2001 Sep; 286(5):916-22. PubMed ID: 11527386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of transforming growth factor on cell cycle regulatory molecules in human myeloid leukemia cells.
    Hu X; Zhang X; Zhong Q; Fisher AB; Bryington M; Zuckerman KS
    Oncogene; 2001 Oct; 20(47):6840-50. PubMed ID: 11687963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accumulation of a form of p27(Kip1) not associated with Cdk-cyclin complexes in transforming growth factor-beta-arrested Mv1Lu cells.
    Taipale M; Tiihonen E; Heiskanen A; Laiho M
    Exp Cell Res; 2000 Aug; 259(1):107-16. PubMed ID: 10942583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
    Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
    Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
    Patel V; Lahusen T; Leethanakul C; Igishi T; Kremer M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS; Senderowicz AM
    Clin Cancer Res; 2002 Nov; 8(11):3549-60. PubMed ID: 12429646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.
    Rao S; Lowe M; Herliczek TW; Keyomarsi K
    Oncogene; 1998 Nov; 17(18):2393-402. PubMed ID: 9811471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mimosine arrests cells in G1 by enhancing the levels of p27(Kip1).
    Wang G; Miskimins R; Miskimins WK
    Exp Cell Res; 2000 Jan; 254(1):64-71. PubMed ID: 10623466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
    Coppock DL; Buffolino P; Kopman C; Nathanson L
    Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines.
    Yoshizawa K; Cioca DP; Kawa S; Tanaka E; Kiyosawa K
    Cancer; 2002 Nov; 95(10):2243-51. PubMed ID: 12412180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncostatin M induces growth arrest by inhibition of Skp2, Cks1, and cyclin A expression and induced p21 expression.
    Halfter H; Friedrich M; Resch A; Kullmann M; Stögbauer F; Ringelstein EB; Hengst L
    Cancer Res; 2006 Jul; 66(13):6530-9. PubMed ID: 16818624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased cdc2 and cdk2 kinase activity by retinoid X receptor gamma-mediated transcriptional down-regulation of the cyclin-dependent kinase inhibitor p21Cip1/WAF1 correlates with terminal differentiation of squamous cell carcinoma lines.
    Crowe DL; Shuler CF
    Cell Growth Differ; 1998 Aug; 9(8):619-27. PubMed ID: 9716179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of F-Box protein p45(SKP2) expression and stabilization of cyclin-dependent kinase inhibitor p27(KIP1) in vitamin D analog-treated cancer cells.
    Lin R; Wang TT; Miller WH; White JH
    Endocrinology; 2003 Mar; 144(3):749-53. PubMed ID: 12586749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limiting amounts of p27Kip1 correlates with constitutive activation of cyclin E-CDK2 complex in HTLV-I-transformed T-cells.
    Cereseto A; Washington Parks R; Rivadeneira E; Franchini G
    Oncogene; 1999 Apr; 18(15):2441-50. PubMed ID: 10229195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.